Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Donor-specific antibodies (DSA) against HLA antigens are well-established predictors of antibody-mediated rejection (ABMR) and graft loss. However, the post-transplant kinetics of preformed DSA and their correlation with clinical outcomes in Indian kidney transplant recipients remain inadequately studied.
This prospective cohort study enrolled 75 renal transplant recipients at a tertiary care center in India. Serum samples were analyzed for HLA Class I and II DSAs at baseline and at 3, 6, and 12 months post-transplant using Luminex single antigen bead assay. Patients were monitored for acute rejection, de novo DSA development, and graft outcomes. Demographic, immunologic, and clinical risk factors were assessed.
Approximately one-fifth of patients experienced rejection during follow-up. De novo DSA developed in 4% of patients—more frequently Class I (2.7%) than Class II (1.3%). A consistent rise in antibody levels was observed predominantly against Class II HLA antigens. Higher DSA titers (MFI ≥1500) were significantly associated with older age (>40 years), prior transplant history, and elevated Flow PRA Class II (≥10%) (p<0.05). No significant correlation was found between rising DSA levels and biopsy-proven rejection. The majority of patients maintained stable graft function at one year.
In this prospective Indian cohort, de novo DSAs occurred infrequently, and their rise was influenced by immunologic sensitization factors but not directly associated with rejection or graft dysfunction within the first year. Serial monitoring of DSA kinetics may help identify high-risk recipients and guide individualized immunosuppression strategies.
